Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?

Basit Öğe Kaydı
dc.authoridDurmus, Mefkure/0000-0001-9745-4196
dc.authoridBahçecioğlu, Ömer Faruk/0000-0002-4045-4555
dc.authorwosidDurmus, Mefkure/ISR-9328-2023
dc.authorwosidBahçecioğlu, Ömer Faruk/AAA-7477-2021
dc.contributor.authorBahcecioglu, Omer Faruk
dc.contributor.authorGok, Selim
dc.contributor.authorDurmus, Mefkure
dc.date.accessioned2024-08-04T20:49:14Z
dc.date.available2024-08-04T20:49:14Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstract[Abstract Not Available]en_US
dc.identifier.doi10.1136/ejhpharm-2021-002680
dc.identifier.issn2047-9956
dc.identifier.issn2047-9964
dc.identifier.issue2en_US
dc.identifier.pmid33472816en_US
dc.identifier.scopus2-s2.0-85099747813en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1136/ejhpharm-2021-002680
dc.identifier.urihttps://hdl.handle.net/11616/99722
dc.identifier.volume28en_US
dc.identifier.wosWOS:000624061900003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBmj Publishing Groupen_US
dc.relation.ispartofEuropean Journal of Hospital Pharmacyen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectdrug-related side effects and adverse reactionsen_US
dc.subjectdrug monitoringen_US
dc.subjectmetabolic side effects of drugs and substancesen_US
dc.subjectdrug substitutionen_US
dc.titleIs it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?en_US
dc.typeLetteren_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu